COMPOSE Study (Neuroendocrine Tumors) - Clinical Trial

Call to Participate

or email

gi-oncology-cru@dm.duke.edu

What is the Purpose of this Study?

Treatment

We are doing this study to compare the study drug, lutetium-177 edotreotide, to existing standard-of-care therapies.

What is the Condition Being Studied?

Objective

Neuroendocrine Tumors

Who Can Participate in the Study?

Key Eligibility

Adults with a gastroenteropancreatic neuroendocrine tumor (GEP-NET) that is:
- Unresectable (cannot be surgically removed)
- Well differentiated
- High grade 2 or grade 3 (Ki-67 index of 15 to 55)
- Somatostatin receptor positive (SSTR+)

For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.

Age Group

Adults

What is Involved?

Description

If you choose to join this study, you will:
- Be assigned to get either the study drug or an existing therapy (CAPTEM, everolimus, or FOLFOX)
- Get up to 6 IV administrations of the study drug 6-8 weeks apart (if assigned) OR take pills and/or get IV administrations of your assigned standard-of-care therapy
- Give blood and urine samples
- Have regular CT or MRI scans

Study Details

Full Title

[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Principal Investigator